Abstract:Recently, PEGylation has been extensively employed to increase the circulation time of liposomes and enhance their accumulation in tumor tissue via the enhanced permeability and retention (EPA) effect; however, poly(ethylene glycol) (PEG) is unfavorable for the uptake of liposomes by tumor cells because of its steric hindrance. In this study, thiolytic cleavable PEG modified liposomes were used to solve this dilemma. Before arrival at the tumor tissue, PEG presents on the surface of liposomes, which is useful for passive accumulation in tumor tissue. Upon reaching the tumor tissues, the PEG chain could be removed by a safe cleaving reagent L-cysteine (L-Cys), and thus, the steric hindrance of PEG could be overcome conveniently. To further improve the uptake of liposomes, a "functional molecule" cell-penetrating peptide TAT was attached to the distal end of a shorter PEG spacer anchored to the surface of the liposomes, which could be shielded by cleavable PEG during circulation; upon arriving at tumor tissue, PEG was removed and thus the "functional molecule" TAT was exposed, and then TAT could mediate the uptake of the liposomes with high efficiency. In this study, thiolytic cleavable PEG was synthesized via a disulfide bridge, DOPE-PEG(1600)-TAT was synthesized by sulfhydryl-maleimide reaction, and then Rh-PE labeled liposomes composed of 2% DOPEPEG(1600)-TAT and various amounts of cleavable PEG(5000) (2%, 4%, and 8%) were prepared, with particle size around 100 nm and slightly negative charge. These liposomes showed good stability in the presence of 10% serum. Their uptake by tumor cells HepG2 in vitro was assessed qualitatively and quantitatively. Liposomes modified with 2% DOPE-PEG(1600)-TAT and 8% DOPES-S-mPEG(5000) were regarded as the optimal formulation. In this preparation, nearly no uptake could be observed before addition of L-Cys, which meant undesired uptake during circulation could be avoided, while the uptake upon addition of L-Cys was 4 times as high as that in the absence of L-Cys. For the uptake in vivo, calcein loaded and Rh-PE labeled 8% cleavable PEG +2% TAT modified liposomes were injected intratumorally into H22 tumor bearing mice. Confocal laser scanning microscopy (CLSM) showed that the uptake of 8% cleavable PEG + 2% TAT modified liposomes was much higher than that of 8% noncleavable PEG + 2% TAT modified liposomes in the presence of L-Cys. Thus, tumor targeted delivery could be achieved efficiently by the liposomal drug delivery system developed here in a controlled manner.

Synergistic Targeted Delivery of Payload into Tumor Cells by Dual-Ligand Liposomes Co-Modified with Cholesterol Anchored Transferrin and TAT.

Targeted Delivery of Cargoes into A Murine Solid Tumor by A Cell-Penetrating Peptide and Cleavable Poly(Ethylene Glycol) Comodified Liposomal Delivery System Via Systemic Administration

Potent cancer therapy by liposome microstructure tailoring with active-to-passive targeting and shell-to-core thermosensitive features

Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes.

Microfluidic Self-Assembly of a Combinatorial Library of Single- and Dual-Ligand Liposomes for in Vitro and in Vivo Tumor Targeting

Dual-Ligand Modification of PEGylated Liposomes Used for Targeted Doxorubicin Delivery to Enhance Anticancer Efficacy

Synergetic Tumor Probes for Facilitating Therapeutic Delivery by Combined-Functionalized Peptide Ligands

Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide

Increased Delivery of Doxorubicin into Tumor Cells Using Extracellularly Activated Tat Functionalized Liposomes: in Vitro and in Vivo Study

Tumor Cells-Specific Targeting Delivery Achieved by A54 Peptide Functionalized Polymeric Micelles

Targeting and microenvironment-responsive lipid nanocarrier for the enhancement of tumor cell recognition and therapeutic efficiency.

Tumor-penetrating Peptide Mediation: an Effective Strategy for Improving the Transport of Liposomes in Tumor Tissue.

Investigation of Dual-Loaded Doxorubicin and Sorafenib Liposomes Co-Modified with Glycyrrhetinic Acid and Cell-Penetrating Peptide TAT

Enhanced Anticancer Efficacy of Dual Drug-Loaded Self-Assembled Nanostructured Lipid Carriers Mediated by pH-Responsive Folic Acid and Human-Derived Cell Penetrating Peptide dNP2

Improved Tumor-Targeting Drug Delivery and Therapeutic Efficacy by Cationic Liposome Modified with Truncated Bfgf Peptide.

Dendritic Lipopeptide Liposomes Decorated with Dual-Targeted Proteins

Tumor-specific penetrating peptides-functionalized hyaluronic acid-d-α-tocopheryl succinate based nanoparticles for multi-task delivery to invasive cancers

Deepened Cellular/subcellular Interface Penetration and Enhanced Antitumor Efficacy of Cyclic Peptidic Ligand-Decorated Accelerating Active Targeted Nanomedicines

The Targeted-liposome Delivery System of Antitumor Drugs

Tumor Targeting Chemo- and Photodynamic Therapy Packaged in Albumin for Enhanced Anti-Tumor Efficacy

Hepatocyte-targeting and Tumor Microenvironment-Responsive Liposomes for Enhanced Anti-Hepatocarcinoma Efficacy.